
March 25 (Reuters) - Corcept Therapeutics shares jumped more than 32% to nearly a two-month high on Wednesday after the U.S. health regulator approved its lead drug for treating an aggressive form of ovarian cancer that no longer responds to standard treatment.
The U.S. Food and Drug Administration approved relacorilant, brand name Lifyorli, for use in combination with the chemotherapy drug nab-paclitaxel.
The therapy is cleared for adults with platinum-resistant epithelial ovarian cancer, a type that returns or progresses within about six months of platinum-based chemotherapy.
Lifyorli works by blocking cortisol-related stress signals in the body, a mechanism that can make cancer cells more responsive to chemotherapy.
The approval was based on a late-stage trial involving 381 patients. The data showed those treated with the combination lived a median of 16 months, compared with 11.9 months for patients receiving chemotherapy alone.
Patients are advised to take 150 mg of the drug on the day before, the day of, and the day after each infusion of nab-paclitaxel, the FDA said.
The treatment carries warnings for low white blood cell counts, serious infections, adrenal insufficiency and potential harm to unborn babies, and should not be used in patients who rely on steroid medications to survive.
UBS analyst Ashwani Verma viewed the approval, which came three months ahead of schedule, as a positive, but said a contraindication for patients on steroid medications could be a hurdle and estimated its peak sales of about $550 million.
In December, the FDA had declined to approve relacorilant for hypertension linked to Cushing's syndrome, saying the drug failed to outperform a placebo and raised concerns about potential liver injury — a setback that sent the company's shares plunging about 50%.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Devika Syamnath and Shilpi Majumdar)
LATEST POSTS
- 1
Huge solar flare no threat to Artemis 2 astronaut launch to the moon, NASA says - 2
What to know about cheese voluntarily recalled in 20 states - 3
Instructions to Pick the Best Course for Your Next Waterway Voyage: Objections, Views, and Social Encounters - 4
Iran war drives global fertilizer prices up, raising food cost fears - 5
Vote In favor of Your Favored Kind Of Bites
China's 'Venice Of The East' Is A Historic Canal City Near Shanghai With Arched Bridges And Lantern-Lit Waterways
Consumer outlook on UK economy falls to two-year low
Impact of NIH funding reductions felt in cancer and infectious disease trials
‘Slender Man’ attacker back in custody. What we know about Morgan Geyser's disappearance and what happens next.
2025 Yachting Editors' Choice Awards: Yachts
Quandoo to shut restaurant booking platform by end of 2026
Was This Driver Simply Having Some good times Or Behaving Like An Ass?
Blue Origin safely launches wheelchair user to space and back
4 Famous Gaming PCs of 2024: Execution, Versatility, and Advancement













